| OSA group | Control group | p-value |
Patients n | 35 | 35 | |
Age yrs | 55.7±1.4 (52.0–58.4) | 56.1±1.4 (53.2–59.2) | ns |
Males/females | 34/1 | 34/1 | ns |
BMI kg·m−2 | 31.9±0.6 (29.4–33.5) | 31.3±0.5 (28.9–33.1) | ns |
Arterial hypertension | | | |
% of patients | 69 | 60 | ns |
Daytime blood pressure mmHg | | | |
Systolic | 136±4 (131–142) | 132±4 (127/138) | ns |
Diastolic | 81±3 (78–84) | 80±2 (77/83) | ns |
Antihypertensive drugs % | 54 | 54 | ns |
Coronary artery disease % | 19 | 23 | ns |
Peripheral occlusive vascular disease % | 3 | 3 | ns |
Smoking | | | |
% of patients | 37 | 60 | ns |
Pack-yrs | 14.4±3.9 (5.3–22.6) | 17.0±3.3 (10.2–26.6) | ns |
Diabetes mellitus | | | |
% of patients | 20 | 37 | ns |
HbA1c % | 6.2±0.2 (5.7–6.7) | 6.1±0.2 (5.7–6.4) | ns |
Antidiabetic drugs % | 14 | 26 | ns |
Hypercholesterolaemia | | | |
% of patients | 59 | 57 | ns |
Total cholesterol mg·dL−1 | 230±7 (216–244) | 219±8 (193–224) | ns |
LDL cholesterol mg·dL−1 | 134±5 (124–145) | 141±6 (129–153) | ns |
HDL cholesterol mg·dL−1 | 42±1 (39–44) | 39±2 (33–42) | ns |
Lipid-lowering drugs % | 17 | 20 | ns |